MAPK1 and ovarian carcinoma: While there have been only few studies concerning DUSP6 and ERK signaling pathway in ovarian cancer, one study presented a result that is contradictory to ours, as it showed that the loss of DUSP6 enhances chemotherapy-resistance in ovarian cancer cells37.